Pain and Opioids: Integrated Treatment In Veterans
Active, not recruitingNot applicableNCT04648228
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This trial will recruit veterans with chronic pain (N = 160) who are prescribed buprenorphine for the treatment of opioid use disorder (OUD). We seek to: (1) examine the efficacy of an integrated treatment to reduce pain interference (Acceptance and Commitment Therapy and Mindfulness-Based Relapse Prevention \[ACT + MBRP\]) compared to an education control (EC) consisting of a protocol-based series of education sessions concerning chronic pain, opioids, and buprenorphine use and (2) examine how theoretically-relevant treatment mechanisms of pain acceptance, engagement in values-based action, and opioid craving are related to treatment outcomes. Interventions will be delivered via the VA Video Connect telehealth modality.
Study details
- Official title
- Integrated Treatment for Veterans With Co-Occurring Chronic Pain and Opioid Use Disorder
- Conditions
- Chronic Pain
- Opioid-use Disorder
- Opioids
- Harmful Use
- Interventions
- Behavioral: ACT+MBRP
- Behavioral: Education control
- Sponsor
- University of New Mexico
- Collaborators
- National Institute on Drug Abuse (NIDA); University of Utah; Johns Hopkins University; Duke University; Vanderbilt University; Biomedical Research Institute of New Mexico; Seattle Institute for Biomedical and Clinical Research; Queen's University, Belfast; University of California, San Francisco; San Francisco VA Health Care System
- Start date
- 2021-07-01
- Primary completion
- 2025-12-16
- Sex
- All
- Age range
- from 21 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 4
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Stabilized on a dose of buprenorphine for a period of at least 1 month and less than six months. Buprenorphine stabilization will be defined as a consistent dose for at least 30 consecutive days. 2. Willing to comply with all study procedures and be available for the duration of the study 3. Male or female, aged 21 to 75 years. 4. Enrolled as a patient in one of the participating VA Co-Occurring Disorders clinics. 5. Presence of chronic pain for \> 6 months in duration. Exclusion Criteria: 1. Current or past diagnosis of schizophrenia, delusional disorder, psychotic or dissociative disorders. 2. Unable to read English. 3. Have a substance use disorder requiring a higher level of care than outpatient treatment (e.g., severe alcohol use disorder requiring inpatient detoxification).
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04648228